Inclusion Criteria:

- Must have recently completed a course of myeloablative therapy followed by autologous
stem cell (bone marrow or peripheral blood) rescue (ASCT)

- Patients must have a diagnosis of neuroblastoma based upon tumor histology or bone
marrow metastases and elevated urine catecholamine metabolites; greater than 98% of
neuroblastomas are GD2-positive without intratumor heterogeneity, so these tumors
will not be immunostained prior to study entry

- Patients entered on CCG-3951 may become eligible following the third course of
high-dose chemotherapy followed by peripheral blood stem cell (PBSC) rescue; patients
treated on institutional (local) protocols of high-dose chemotherapy with PBSC rescue
may also become eligible after one or more courses of PBSC rescue

- Patients must enter onto study within 8 weeks after the total absolute phagocyte
count [neutrophils (segs + bands) + monocytes] is > 1,000/uL; the APC criteria
include counts obtained while on G-CSF therapy

- Patients must have a performance status of 0, 1 or 2 and patients must have a life
expectancy of >= 2 months

- Serum creatinine =< 1.5 x normal, or creatinine clearance or radioisotope glomerular
filtration rate (GFR) >= 60 ml/min/1.73 m^2

- Total bilirubin =< 1.5 x normal

- Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or
serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 5 x
normal

- Veno-occlusive disease, if present, should be stable or improving

- Shortening fraction of >= 27% by echocardiogram, or ejection fraction of > 50% by
gated radionuclide study

- Forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) > 60% of
predicted by pulmonary function test

- For children who are unable to do pulmonary function tests (PFTs), no evidence of
dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% on room air

- Patients with seizure disorder may be enrolled if on anticonvulsants and well
controlled

- Central nervous system (CNS) toxicity < grade 2

- Patients must have a double lumen catheter or single lumen and peripheral IV so that
interleukin (IL)-2 and ch14.18 can be given separately

- Patients who remain evaluable for response on Phase II/III studies (i.e. CCG-3891)
are not eligible for this study; however, patients treated on Phase I studies (i.e.
CCG-3951) and patients who are no longer evaluable on Phase II/III studies (i.e.
progressive disease following therapy) will be eligible

- Patients who were previously treated with antibody 14.G2a or ch14.18 are ineligible
for this study

- Patients requiring chronic use of corticosteroids are ineligible

- Corticosteroid, immunosuppressive drugs, myelosuppressive chemotherapy, and retinoic
acid must not be given within 14 days prior to study entry

- Radiation therapy must not be given within seven days prior to study entry or during
therapy

- All patients and/or their parents or legal guardians must sign a written informed
consent

- All institutional, FDA, and NCI requirements for human studies must be met